Trial Profile
A Phase III Double Blind Randomized Placebo Controlled Study of Trastuzumab as Short Duration Preoperative Therapy in Patients With HER2-neu Positive Operable Breast Cancer
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 07 Oct 2020 Planned End Date changed from 1 Feb 2021 to 1 Feb 2027.
- 07 Oct 2020 Planned primary completion date changed from 1 Apr 2020 to 1 Apr 2025.
- 24 Apr 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Apr 2020.